HGF mimetic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-05. Numbers and descriptions here follow the published literature rather than marketing material.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Stored desiccated before use |
| Recommended storage | -20 °C | Protect from light and moisture |
| Common stock solvent | Dimethyl sulfoxide | Aqueous solubility may be limited |
| Purity method | Reverse-phase HPLC | Reports percent purity and impurities |
| Identity method | Mass spectrometry | Confirms molecular mass |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
== History == Urea was first obtained by Herman Boerhaave in 1727 from evaporates of urine. The discovery is also attributed to the French chemist Hilaire Rouelle as well as William Cruickshank. In 1773, Hilaire Rouelle obtained crystals containing urea by evaporating human urine and treating the concentrate with alcohol. This method was aided by Carl Wilhelm Scheele's discovery that crystals precipitated when urine was treated by concentrated nitric acid. Uremic frost was first described in 1856 by the Austrian physician Anton Drasche. Uremic frost has become rare since the advent of dialysis. It is the classical pre-dialysis era description of crystallized urea deposits over the skin of patients with prolonged kidney failure and severe uremia.
== See also == Analytical chemistry – Study of the separation, identification, and quantification of matter Chemical process – A method or means of somehow changing one or more chemicals or chemical compounds. High-performance liquid chromatography – Technique in analytical chemistry Unit operation – Basic step in a process Filtration – Process that separates solids from fluids
In 2002 David Evans et al. observed a very stable neutral tetrahedral intermediate in the reaction of N-acylpyrroles with organometallic compounds, followed by protonation with ammonium chloride producing a carbinol. The C1-N1 bond [147.84(14) pm] is longer than the usual Csp3-Npyrrole bond which range from 141.2-145.8 pm. In contrast, the C1-O1 bond [141.15(13) pm] is shorter than the average Csp3-OH bond which is about 143.2 pm. The elongated C1-N1, and shortened C1-O1 bonds are explained with an anomeric effect resulting from the interaction of the oxygen lone pairs with the σ*C-N orbital. Similarly, an interaction of an oxygen lone pair with σ*C-C orbital should be responsible for the lengthened C1-C2 bond [152.75(15) pm] compared to the average Csp2-Csp2 bonds which are 151.3 pm. Also, the C1-C11 bond [152.16(17) pm] is slightly shorter than the average Csp3-Csp3 bond which is around 153.0 pm.
Events in 1958 – notably a riot during Vice President Nixon's visit to Caracas, Venezuela, in May 1958 – resulted in a reversal of the U.S. position in August 1958. With U.S. support, in April 1959 the Organization of American States created the Inter-American Development Bank, most of whose capital was contributed by the borrowing countries. To further engage other wealthy countries in development assistance, the United States supported the creation of the Aid India Consortium in August 1958. This was the first of several informal groupings of donors focussing on particular countries. The United States also encouraged Western Europe and Japan to increase their development assistance by building on the European Marshall Plan organization, the Organization of European Economic Cooperation (OEEC). The OEEC had been created in 1948 by recipients of Marshall Plan aid, at the request of the United States government, to decide on allocation of that aid within Europe, and by the late 1950s it had fulfilled its original mandate. In January 1960, Eisenhower and Under Secretary of State C. Douglas Dillon got agreement from OEEC members to create a Development Assistance Group composed of the OEEC members who were the main sources of development assistance, along with non-members who were major donors – the U.S., Canada, and Japan. In 1961, the OEEC itself was restructured to become the Organisation for Economic Co-operation and Development, which established a Development Assistance Committee (DAC) as a restructured DAG that was brought under the OECD.
Sources: en.wikipedia.org
=== NNR === Research overview: This study involves creating a combination of model membranes which contain 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-distearoly-sn-glycero-3-phosphocholine (DSPC) referred to as the "host membranes", phospholipids labeled as 1,2,& 3 referred to as "exchanging molecules" or "reporting molecules" and varied cholesterol mole percentages in the presence of an aqueous solution containing 5% ethanol (v/v). The host membranes were chosen because their phase diagrams are well understood and have been extensively characterized by different analytical techniques.6 The nearest neighbor recognition technique is being applied to the formation of the modeled membranes to observe the association between cholesterol and phospholipids as well as the effects that the presence of ethanol has against this interaction. Researchers are observing whether or not ethanol enhances or disrupts the liquid-ordered phase by reorganizing this formation into a liquid-disordered phase. The liquid-ordered phase is similar to a lamellar phase and the liquid-disordered phase represents the non-lamellar phases but the exact type of each phase (hexagonal, cubic, etc.) is not described. As previously mentioned several different combinations of the host membranes, exchanging molecules, and cholesterol are created to form the model membranes. It is important to mention that the exchanging molecules selected have similar properties to the host membranes.
On 22 February 2026, El Mencho was killed by the Mexican military in Tapalpa, Jalisco. Widespread violence erupted in Mexico as a result of retaliation attacks from the CJNG. Mexico City-based security consultant David Saucedo informed CNN that due to El Mencho's son Rubén Oseguera González ("El Menchito") being jailed in the United States, the line of succession "has been broken," with no clear family successor. The arrest of El Menchito would leave only one brother and El Mencho's stepson Juan Carlos Valencia Gonzalez ("El Pelón"), though El Pelon lacked "influence among other cartel commanders." Saucedo stated that was "likely that one of four or five top commanders will emerge as the next leader," and named CJNG leaders Ricardo Ruiz Velasco ("El Doble R"), Audias Flores ("El Jardinero" or "The Gardener"), Hugo Mendoza Gaytan ("El Sapo") and a fourth figure – El Mencho's former head of security – about whom little is known, as the most likely candidates to succeed El Mencho. In addition it was soon afterwards revealed by El Pais that El Mencho's brother Abraham, who was arrested in Mexico in February 2025, was actually in fact still "in the hands of Mexican authorities." The U.S. Director of National Intelligence's (DNI) National Counterterrorism Center has stated that El Pelón was the "de facto second-in-command" to El Mencho, with $5 million bounties being issued each for El Pelon and El Jardinero.
== Molecular problem: fibrosis == When faced with pressure overload, the heart attempts to compensate with a number of structural alterations including hypertrophy of cardiomyocytes and increase of extracellular matrix (ECM) proteins. Rapid accumulation of ECM proteins causes excessive fibrosis resulting in decreased myocardial compliance and increased myocardial stiffness. The exact mechanisms involved in excessive fibrosis are not fully understood but there is evidence that supports involvement from local growth factors FGF-2, TGF-beta and platelet-derived growth factor. TGF-β1 plays an important role in cardiac remodelling through the stimulation of fibroblast proliferation, ECM deposition and myocyte hypertrophy. The increase in TGF-beta 1 expression in a pressure-overloaded heart correlates with the degree of fibrosis, suggesting TGF-beta 1 involvement in the progression from a compensated hypertrophy to failure. Through an autocrine mechanism, TGF-beta 1 acts on fibroblasts by binding TGF-beta 1 receptors 1 and 2. Upon receptor activation, the receptor-associated transcription factor Smad becomes phosphorylated and associates with Co-Smad. This newly formed Smad-Co-Smad complex enters the nucleus where it acts as a transcription factor modulating gene expression. Cardiac remodelling of the ECM is also regulated by the CNP/NPR-B pathway as demonstrated by the improved outcomes in transgenic mice with CNP over-expression subjected to myocardial infarction.
Sources: en.wikipedia.org
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.
Mass spectrometry is commonly used to confirm molecular mass, while reverse-phase HPLC assesses purity. Some laboratories also use nuclear magnetic resonance for structural verification. These methods are standard for research peptides.
Aqueous solubility can be limited and varies by batch and salt form. Dimethyl sulfoxide is often used for stock solutions. Supplier documentation or a solubility test can clarify behavior for a given lot.
It is thought to enhance hepatocyte growth factor signaling through the c-Met receptor. This pathway is involved in cell growth and repair. The precise molecular details are not fully established.